Depressive Disorder, Major
Conditions
Brief summary
The purpose of this study is to assess the efficacy of flexibly dosed JNJ-42847922 (20 milligram \[mg\] or 40 mg) compared to flexibly dosed quetiapine extended-release (XR) (150 mg or 300 mg) as adjunctive therapy to an antidepressant drug in delaying time to all-cause discontinuation of study drug over a 6-months (24 weeks) treatment period, in participants with major depressive disorder (MDD) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Interventions
DRUGJNJ-42847922
Participants will receive JNJ-42847922 capsule orally.
DRUGPlacebo Matching to JNJ-42847922
Participants will receive placebo capsule matching to JNJ-42847922 orally.
DRUGQuetiapine XR
Participants will receive quetiapine XR capsule orally.
DRUGPlacebo Matching to Quetiapine XR
Participants will receive placebo capsule matching to quetiapine XR orally.
Participants will receive SSRI antidepressant (such as, citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine, sertraline, vilazodone or vortioxetine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
DRUGSerotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Participants will receive SNRI antidepressant (such as duloxetine, milnacipran, levomilnacipran, venlafaxine, desvenlafaxine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
Sponsors
Janssen Research & Development, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Male or female of non-childbearing potential (WONCBP) outpatients, aged 18 to 70 years (inclusive). A WONCBP is defined as: a).Postmenopausal: A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. b). Permanently sterile: Permanent sterilization methods include hysterectomy, bilateral salpingectomy, bilateral tubal occlusion/ligation procedures, and bilateral oophorectomy. c). If reproductive status is questionable, additional evaluation should be considered * Meet Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the Structured Clinical Interview for DSM-5 Axis I Disorders- Clinical Trials Version (SCID-CT). The length of the current depressive episode must be less than or equal to (\<=) 18 months * Have had an inadequate response to at least 1 but no more than 3 antidepressants, administered at an adequate dose and duration in the current episode of depression, as assessed by the Massachusetts General Hospital-Antidepressant Treatment Response Questionnaire (MGH-ATRQ). An inadequate response is defined as less than (\<)50 percent (%) reduction in depressive symptom severity, as assessed by the MGH-ATRQ. An adequate trial is defined as an antidepressant treatment for at least 4 weeks at or above the minimum therapeutic dose, as specified in the MGH-ATRQ, for any particular antidepressant. The inadequate response must include the participant's current antidepressant treatment * Be receiving monotherapy treatment for depressive symptoms with 1 of the following selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressants, in any formulation: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at or above the minimum therapeutic dose level) for at least 4 weeks, and for no greater than 12 months, at screening. Modification of an effective preexisting therapy should not be made for the explicit purpose of entering a participant into the study * Have a Montgomery-Asberg Depression Rating Scale (MADRS) total score greater than or equal to (\>=)25 (performed by independent, centralized remote raters) at screening and must not demonstrate a clinically significant improvement (that is, an improvement of greater than (\>)20% on their MADRS total score) from the screening to baseline visit * Have a Body Mass Index (BMI) between 18 and 35 kilogram per meter square (kg/m\^2) inclusive (BMI equal to \[=\] weight/height\^2) * Must be otherwise healthy on the basis of physical examination, medical history, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory tests performed at screening. If there are abnormalities, they must be consistent with the underlying illness in the study population. If the results of the clinical laboratory tests are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator
Exclusion criteria
* Have Cushing's Disease, Addison's Disease, primary amenorrhea, or other evidence of significant medical disorders of the hypothalamic-pituitary-adrenal (HPA) axis * Have a history of epilepsy, neuroleptic malignant syndrome (NMS) or Tardive Dyskinesia * Have a history of previous non-response to an adequate trial of quetiapine as an adjunctive treatment for MDD (adequate trial defined as \>=150 mg for 4 weeks or more) and/or a history of lack of response to 3 or more adequate antidepressant treatments and/or a history or evidence of noncompliance with current antidepressant therapy * Have taken a known moderate or strong inhibitor/inducer of cytochrome P450 (CYP)3A4 and CYP2C9 or a dual inhibitor/inducer of CYP3A4 and CYP2C9 within 14 days (or after washout that is, duration of 5 times the drug's half-life) before the first study drug administration on Day 1 until the follow-up visit. Fluvoxamine is a moderate CYP2C9 inhibitor and a mild CYP3A inhibitor, and will not be excluded from the study * Have a history or current diagnosis of a psychotic disorder, bipolar disorder, intellectual disability, autism spectrum disorder, borderline personality disorder, somatoform disorders, or fibromyalgia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to All-Cause Discontinuation of Study Drug | Up to Week 24 | Time to all-cause discontinuation of study drug is defined as the number of days from the first dose of study drug to the last dose of study drug. Participants who completed double-blind treatment were not considered to have discontinued. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Shifts in Triglycerides From Normal to High | Up to Week 24 | Percentage of participants with shifts in triglycerides from normal to high (\<150 milligrams per deciliter \[mg/dL\] at baseline to \>=200 mg/dL at any post-baseline assessment) were reported. |
| Percentage of Participants With Sustained Response up to Week 24 | Up to Week 24 | A participant was defined as having achieved a sustained response if there was at least a 50% improvement from baseline in the MADRS total score at Week 12, and that response was maintained at Week 18 and Week 24. Participants who did not meet such criterion were considered as non-sustained responders. MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. |
| Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline Insomnia Severity Index [ISI] Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score Less Than [<] 15) at Week 12 | Baseline and Week 12 | MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition. |
| Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISI Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score <15) at Week 18 | Baseline and Week 18 | MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition. |
| Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISIscore >=15) Versus Those Without Significant Insomnia (Baseline ISI Score 15) at Week 24 | Baseline and Week 24 | MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition. |
| Change From Baseline in the Hamilton Anxiety Rating Scale (HAM-A) Total Score at Weeks 12, 18, and 24 | Baseline, Weeks 12, 18, and 24 | HAM-A is a 14-item scale designed to measure anxiety in individuals. Each question reflects a symptom of anxiety and physical as well as mental symptoms are represented. Each of the 14-items in the scale is scored on a 5-point scale, ranging from 0 (a complete lack of that symptom) to 4 (a very severe show of anxiety with that symptom). The total score ranges from 0 to 56 which is calculated by adding the scores of all 14 items, where 0-13 indicates normal range, 14-17 indicates mild severity, 18 -24: mild to moderate severity, 25 -30: moderate to severe, and \>=31: severe. Higher score indicates worsening. Negative change in score indicates improvement. |
| Percentage of Participants With Weight Gain of >=7% of Baseline Body Weight at Week 24 | At Week 24 | Percentage of participants with weight gain of \>=7% of baseline body weight at Week 24 were reported. |
| Percentage of Participants With Shifts in Triglycerides From Borderline to High | Up to Week 24 | Percentage of participants with shifts in triglycerides from borderline to high (\>=150 to \<200 mg/dL at baseline to \>=200 mg/dL at any post-baseline assessment) were reported. |
| Percentage of Participants With Shifts in Triglycerides From Normal to Very High | Up to Week 24 | Percentage of participants with shifts in triglycerides from normal to very high (\<150 mg/dL at baseline to \>=500 mg/dL at any post-baseline assessment) were reported. |
| Percentage of Participants With Shifts in Triglycerides From Borderline to Very High | Up to Week 24 | Percentage of participants with shifts in triglycerides from borderline to very high (\>=150 mg/dL to \<200 mg/dL at baseline to \>=500 mg/dL at any post-baseline assessment) were reported. |
| Percentage of Participants With Shifts in Triglycerides From High to Very High | Up to Week 24 | Percentage of participants with shifts in triglycerides from high to very high (\>=200 mg/dL to \<500 mg/dL at baseline to \>=500 mg/dL at any post-baseline assessment) were reported. |
| Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to Borderline | Up to Week 24 | Percentage of participants with shifts in fasting blood glucose from normal to borderline (\<100 mg/dL at baseline to between \>=100 and \<126 mg/dL at any post-baseline assessment) were reported. |
| Percentage of Participants With Shifts in Fasting Blood Glucose From Borderline to High | Up to Week 24 | Percentage of participants with shifts in fasting blood glucose from borderline to high (\>=100 to \<126 mg/dL at baseline to \>=126 mg/dL at any post-baseline assessment) were reported. |
| Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to High | Up to Week 24 | Percentage of participants with shifts in fasting blood glucose from normal to high (\<100 mg/dL at baseline to \>=126 mg/dL at any post-baseline assessment) were reported. |
| Change From Baseline in the Clinical Global Impression-Severity (CGI-S) Scale Score at Weeks 12 and 24 | Baseline, Weeks 12 and 24 | The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S is a 7-point global assessment scale that measures the clinician's impression of the severity of illness exhibited by a participant, rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. Higher scores indicate worsening. Negative change in score indicates improvement. |
| Change From Baseline in the Patient Global Impression Severity (PGI-S) Scale Score at Weeks 12 and 24 | Baseline, Weeks 12 and 24 | The PGI-S is a self-report scale to measure severity of illness (1=none, 2=mild, 3=moderate, 4=severe). Higher score indicates more illness severity. Negative change in score indicates improvement. |
| Change From Baseline in Quality of Life in Depression Scale (QLDS) Score at Weeks 12 and 24 | Baseline, Weeks 12 and 24 | The QLDS is a disease specific patient-reported outcome (PRO) designed to assess health related quality of life in participants with major depressive disorder (MDD). The instrument has a recall period of at the present time, contains 34-items with true/not true response options. Each statement on the QLDS is given a score of 1 (adverse quality of life) or 0 good quality of life. All item scores are summed to give a total score that ranges from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition. Negative change indicates improvement. |
| Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form 8a at Weeks 12 and 24 | Baseline, Weeks 12 and 24 | The PROMIS-SD Short Form 8a subscale consists of a static 8 item questionnaire. It assesses the concepts of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items) and worrying about sleep (1 item). Responses to each of the 8 items range from 1 to 5, and the range of possible summed raw scores is 8 to 40. Higher scores on the PROMIS-SD indicate more of the concept measured (disturbed sleep). Negative change in score indicates improvement. |
| Percentage of Participants With Sustained Remission up to Week 24 | Up to Week 24 | Remission is defined as Montgomery-Asberg Depression Rating Scale (MADRS) total score of less than or equal to (\<=) 12. A participant was defined as having achieved sustained remission if the MADRS total score was ≤12 at Week 12 and was sustained at Weeks 18 and 24. Participants with missing values at a given time point were imputed as non-evaluable for remission. MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. |
| Change From Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Score at Weeks 12 and 24 | Baseline, Weeks 12 and 24 | The SMDDS assesses participant-reported symptoms associated with MDD. This 16-item instrument has a 7-day recall period, and participants respond to each question using a rating scale between 0 (Not at all or Never) to 4 (Extremely or Always). Before summing the items to create a total score, item 11 (how often did you have a poor appetite) and item 12 (how often did you over eat) are combined into a single score by selecting the highest severity on either item. The total score is then created by summing the responses on the 15 items. The total score ranges from 0 to 60 with a higher score indicating more severe depressive symptomatology. Negative change in score indicates improvement. |
| Change From Baseline in Symbol Digit Modalities Test (SDMT) at Weeks 6, 12, and 24 | Baseline, Weeks 6, 12, and 24 | SDMT is a widely used, paper-and-pencil assessment of complex scanning and visual tracking, requiring elements of attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The test is viewed as a robust screening test for adult neuropsychological impairment and is sensitive to impairments in cognitive function associated with MDD. The SDMT measured the time to pair abstract symbols with specific numbers. The test included a coding key consisting of 9 abstract symbols, each paired with a number ranging from 1 to 9. Following the key, the participant was presented with randomly ordered symbols and was required to write the number corresponding to each symbol as fast as possible. The number of correct substitutions within 90 seconds was recorded and total score derived from the total number of correct responses with a minimum possible score of 0 and maximum of 110 where high scores indicate better outcome. Positive change in score indicates improvement. |
| Change From Baseline in Trail Making Test - Part B (TMT-Part B) at Weeks 6, 12, and 24 | Baseline, Weeks 6, 12, and 24 | The TMT-Part B measures divided attention and executive function (tracking and sequencing). The participant is instructed to draw a line to connect a set of 25 consecutively numbered and lettered circles, alternating sequentially between numbers and letters (that is, 1 A 2 B). The participant is instructed to work as quickly as possible while still maintaining accuracy. Score included time (seconds) to completion and number of errors in performing the test which ranges from 0 (no errors) to 25 (more errors), where shorter time and less number of errors indicates better performance. The TMT-Part B is sensitive to cognitive decline associated with MDD. Negative change in score indicates improvement. |
| Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Baseline, Weeks 6, 12, and 24 | The HVLT-R measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the total number of true-positive errors (0-12); and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score indicates higher cognition. |
| Change From Baseline in Salivary Cortisol Levels as Measured at Home Upon Awakening and During the Evening at Weeks 6 and 24 | Baseline, Weeks 6 and 24 | Change from baseline in salivary cortisol levels as measured upon awakening and at home during the evening at Weeks 6 and 24 were reported. |
| Percentage of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability | Up to 24 weeks | An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs were AEs with onset during the double-blind treatment phase or that were a consequence of a preexisting condition that worsened since baseline. |
| Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) and Events of Special Interest | Up to 24 weeks | An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. AESIs were significant AEs that were judged to be of special interest because of clinical importance, known or suspected class effects, or based on nonclinical signals. Adverse events of special interest were cataplexy, sleep paralysis, complex, and sleep-related behaviors (parasomnias). |
| Percentage of Participants With Abnormalities in Vital Sign Parameters | Up to 24 weeks | Percentage of participants with abnormalities in vital sign parameters (pulse, supine and standing blood pressure \[systolic and diastolic\], body temperature, and body weight) were reported. Abnormally low values for parameters included pulse (beats per minute)- decrease value from baseline (\>=) 15 to \<=50; Systolic Blood Pressure (BP) (mmHg \[Millimeter of mercury\])- decrease value from baseline \>=20 to \<=90; Diastolic BP- decrease value from baseline \>=15 to \<=50; weight (Kilogram\[Kg\])- decrease from baseline of \>=7%; Body temperature (Celsius \[C\])- \<35.5. Abnormally high values for parameters included pulse- increase value from baseline \>=15 to \>=100; Systolic BP(mmHg)- increase from baseline of \>=20 to \>=180; Diastolic BP- increase value from baseline \>=15 to \>=105; weight(Kg)- increase from baseline of \>=7%; body temperature (C)- \>37.5. |
| Percentage of Participants With Abnormalities in Electrocardiogram (ECG) Parameters | Up to 24 weeks | Percentage of participants with abnormalities in ECG parameters were reported. |
| Percentage of Participants With Abnormalities in Clinical Laboratory Parameters | Up to 24 weeks | Percentage of participants with abnormalities in clinical laboratory parameters were reported. |
| Percentage of Participants With Sexual Dysfunction as Determined by Arizona Sexual Experiences Scale (ASEX) Total Score | Up to Endpoint (Up to 24 weeks) | Sexual dysfunction is defined as an ASEX total score of 19 or greater, or a score of 5 or greater on any item, or a score of 4 or greater on any 3 items. ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Each of the 5 items is rated on a 6-point Likert scale, ranging from 1 to 6. The 5 items are summed to create a total score, ranging from 5 to 30, with the higher scores indicating more sexual dysfunction. |
| Percentage of Participants With Clinically Relevant Changes in Extrapyramidal Symptoms Assessed by the Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Score | Up to Endpoint (Up to 24 weeks) | The ESRS-A is an abbreviated manualized version of the ESRS, a semi-structured interview that rates parkinsonian symptoms, dystonia, dyskinesias, and akathisia over the previous 7 days. The ratings include a motor examination for rigidity, tremor, reduced facial expression or speech, impaired gait/posture, postural instability, and bradykinesia/hypokinesia. Twenty-four individual items are rated on a 6-point scale: 0=Absent, 1=Minimal, 2=Mild, 3=Moderate, 4=Severe, or 5=Extreme. Frequency is included as an index of severity. |
| Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | Up to Endpoint (Up to 24 weeks) | C-SSRS is a clinician-rated instrument that reports severity and frequency of suicide-related ideation and behaviors. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (non-specific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 6 (preparatory acts or behavior), 7 (aborted attempt), 8 (interrupted attempt), 9 (actual attempt \[non-fatal\]), and 10 (completed suicide \[only applicable for post baseline\]). Minimum total score 0, maximum total score 10; higher total scores indicate more suicidal ideation and/or suicidal behavior. If no events qualify for score of 1 to 10, score of 0 was assigned (0= no event that can be assessed on the basis of C-SSRS). Higher scores indicate greater severity. |
| Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Up to 26 weeks | Intensity of discontinuation symptoms was assessed (anxiety-nervousness, dysphoric mood/depression, Depersonalization-Derealization, , Diaphoresis, Diarrhea, Difficulty Concentrating, Remember, Dizziness-Lightheadedness, Fatigue-Lethargy-Lack of Energy, Headaches, Increased Acuity Sound Smell Touch, Irritability, Loss of Appetite, Muscle Aches or Stiffness, Nausea-Vomiting, Paresthesias, Poor Coordination, Restlessness-Agitation, Tremor-Tremulousness, Weakness), using the Physician Withdrawal Checklist (PWC-20) administered by a trained clinician/rater. Symptoms are rated on a scale of 0 (no symptom present), 1 (mild), 2 (moderate), and 3 (severe). Total scores range from 0 (no symptom) to 24 (severe symptom) calculated by adding the scores of following 8 items: Nausea-Vomiting, Diarrhea, Poor Coordination, Diaphoresis, Tremor-Tremulousness, Dizziness-Lightheadedness, Increased Acuity Sound Smell Touch, Paresthesias. Higher scores indicates more severe symptoms. |
| Change From Baseline in MADRS Total Score Over Time | Baseline, Weeks 2, 4, 6, 12, 18, 24 | MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. |
| Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Baseline, Weeks 2, 4, 6, 12, 18, 24, and 26 | MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. Negative change in score indicates improvement. |
| Change From Baseline in MADRS-6 Score Over Time | Baseline, Weeks 2, 4, 6, 12, 18, 24, and 26 | MADRS-6 is the depression subscale of the full MADRS, including the following 6 items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, pessimistic thoughts. Each item is scored from 0 (absence of symptom) to 6 (severe symptom); the overall score ranges from 0 to 36 which is calculated by adding the scores of all 6 items. Higher scores represent a more severe condition. |
| Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Related Impairment (PROMIS-SRI) Short Form 8a at Weeks 12 and 24 | Baseline, Weeks 12 and 24 | The PROMIS-SRI Short Form 8a subscale consists of a static 8 item questionnaire and use five-point likert scale to capture the participant's impressions. It assesses sleep-related impairment over the past 7 days. Responses to each of the 8 items range from 1 (less impairment) to 5 (more impairment), and the range of possible summed raw scores is 8 to 40. Lower scores indicate less sleep related impairment. Negative change in score indicates improvement. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Seltorexant Participants in the double-blind treatment phase received seltorexant 20 milligrams (mg) tablet orally once daily as the starting dose on Day 1. From Day 14, participants received either seltorexant 20 mg or 40 mg up to Day 168 (Week 24) while continuing their current selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant on which they had an inadequate response at the time of screening. Participants had a follow-up visit within 7 to 14 days after double-blind treatment phase. During the follow-up phase, participants were followed-up for the safety assessments on Day 182 (Week 26). | 52 |
| Quetiapine XR Participants in the double-blind treatment phase received quetiapine XR 50 mg once daily for the first two days and then 150 mg tablets orally once daily from Day 3 to Day 14. From Day 14, participants received either quetiapine XR 150 mg or 300 mg up to Day 168 (Week 24) while continuing their current selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant on which they had an inadequate response at the time of screening. Participants had a follow-up visit within 7 to 14 days after double-blind treatment phase. During the follow-up phase, participants were followed-up for the safety assessments on Day 182 (Week 26). | 52 |
| Total | 104 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Double-blind Treatment Phase (24 Weeks) | Adverse Event | 7 | 8 |
| Double-blind Treatment Phase (24 Weeks) | Death | 1 | 0 |
| Double-blind Treatment Phase (24 Weeks) | Lack of Efficacy | 1 | 3 |
| Double-blind Treatment Phase (24 Weeks) | Lost to Follow-up | 2 | 2 |
| Double-blind Treatment Phase (24 Weeks) | Non-Compliance with Study Drug | 3 | 6 |
| Double-blind Treatment Phase (24 Weeks) | Other | 1 | 4 |
| Double-blind Treatment Phase (24 Weeks) | Withdrawal by Subject | 9 | 3 |
| Follow-up Phase (2 Weeks) | Other | 24 | 24 |
Baseline characteristics
| Characteristic | Seltorexant | Quetiapine XR | Total |
|---|---|---|---|
| Age, Continuous | 55.3 years STANDARD_DEVIATION 9.67 | 53.6 years STANDARD_DEVIATION 10.83 | 54.5 years STANDARD_DEVIATION 10.26 |
| Age, Customized 85 years and over | 0 Participants | 0 Participants | 0 Participants |
| Age, Customized Adults (18-64 years) | 43 Participants | 43 Participants | 86 Participants |
| Age, Customized From 65 to 84 years | 9 Participants | 9 Participants | 18 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 17 Participants | 10 Participants | 27 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 34 Participants | 41 Participants | 75 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 14 Participants | 14 Participants | 28 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 2 Participants | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 2 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 36 Participants | 36 Participants | 72 Participants |
| Region of Enrollment UNITED STATES | 52 Participants | 52 Participants | 104 Participants |
| Sex: Female, Male Female | 34 Participants | 35 Participants | 69 Participants |
| Sex: Female, Male Male | 18 Participants | 17 Participants | 35 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 52 | 0 / 52 | 0 / 52 | 0 / 52 |
| other Total, other adverse events | 21 / 52 | 32 / 52 | 1 / 52 | 2 / 52 |
| serious Total, serious adverse events | 1 / 52 | 2 / 52 | 0 / 52 | 0 / 52 |
Outcome results
Primary
Time to All-Cause Discontinuation of Study Drug
Time to all-cause discontinuation of study drug is defined as the number of days from the first dose of study drug to the last dose of study drug. Participants who completed double-blind treatment were not considered to have discontinued.
Time frame: Up to Week 24
Population: Full analysis set included all randomized participants who received at least 1 dose of study drug except 2 participants who received potentially defective investigational products (IPs) and were subsequently discontinued early because of the IP issues.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Seltorexant | Time to All-Cause Discontinuation of Study Drug | NA days |
| Quetiapine XR | Time to All-Cause Discontinuation of Study Drug | NA days |
p-value: 0.5355Log Rank
Secondary
Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24
The HVLT-R measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the total number of true-positive errors (0-12); and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score indicates higher cognition.
Time frame: Baseline, Weeks 6, 12, and 24
Population: Full analysis set included all randomized participants who received at least 1 dose of study drug except 2 participants who received potentially defective IPs and were subsequently discontinued early because of the IP issues. Here, 'N' (numbers of participants analyzed) signifies numbers of participants evaluable for this outcome measure; 'n' (number analyzed) signifies those participants who were evaluable at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Seltorexant | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Delayed Recall: Week 6 | 0.2 units on a scale | Standard Deviation 2.07 |
| Seltorexant | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Recognition Discrimination Index: Week 12 | -0.3 units on a scale | Standard Deviation 4.67 |
| Seltorexant | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Delayed Recall: Week 12 | 0.5 units on a scale | Standard Deviation 2.54 |
| Seltorexant | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Total Recall: Week 24 | 2.0 units on a scale | Standard Deviation 5.22 |
| Seltorexant | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Total Recall: Week 12 | 1.9 units on a scale | Standard Deviation 5.24 |
| Seltorexant | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Delayed Recall: Week 24 | 1.3 units on a scale | Standard Deviation 2.74 |
| Seltorexant | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Total True-Positive Errors: Week 24 | 0.5 units on a scale | Standard Deviation 3.03 |
| Seltorexant | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Total True-Positive Errors: Week 6 | 0.5 units on a scale | Standard Deviation 4.21 |
| Seltorexant | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Total True-Positive Errors: Week 12 | 0.2 units on a scale | Standard Deviation 3.99 |
| Seltorexant | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Recognition Discrimination Index: Week 6 | 0.8 units on a scale | Standard Deviation 4.03 |
| Seltorexant | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Recognition Discrimination Index: Week 24 | 0.9 units on a scale | Standard Deviation 2.91 |
| Seltorexant | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Total Recall: Week 6 | 0.6 units on a scale | Standard Deviation 4.6 |
| Quetiapine XR | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Recognition Discrimination Index: Week 24 | -0.3 units on a scale | Standard Deviation 4.69 |
| Quetiapine XR | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Total Recall: Week 6 | -0.1 units on a scale | Standard Deviation 5.51 |
| Quetiapine XR | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Total Recall: Week 12 | 1.3 units on a scale | Standard Deviation 5.25 |
| Quetiapine XR | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Total Recall: Week 24 | 1.4 units on a scale | Standard Deviation 5.09 |
| Quetiapine XR | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Total True-Positive Errors: Week 6 | -0.4 units on a scale | Standard Deviation 2.71 |
| Quetiapine XR | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Total True-Positive Errors: Week 12 | -0.1 units on a scale | Standard Deviation 3.59 |
| Quetiapine XR | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Recognition Discrimination Index: Week 6 | 1.0 units on a scale | Standard Deviation 3.8 |
| Quetiapine XR | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Recognition Discrimination Index: Week 12 | 0.1 units on a scale | Standard Deviation 5.29 |
| Quetiapine XR | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Delayed Recall: Week 6 | 0.6 units on a scale | Standard Deviation 2.57 |
| Quetiapine XR | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Delayed Recall: Week 12 | 1.0 units on a scale | Standard Deviation 2.52 |
| Quetiapine XR | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Delayed Recall: Week 24 | 1.4 units on a scale | Standard Deviation 2.39 |
| Quetiapine XR | Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24 | Total True-Positive Errors: Week 24 | -0.7 units on a scale | Standard Deviation 3.07 |
Secondary
Change From Baseline in MADRS-6 Score Over Time
MADRS-6 is the depression subscale of the full MADRS, including the following 6 items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, pessimistic thoughts. Each item is scored from 0 (absence of symptom) to 6 (severe symptom); the overall score ranges from 0 to 36 which is calculated by adding the scores of all 6 items. Higher scores represent a more severe condition.
Time frame: Baseline, Weeks 2, 4, 6, 12, 18, 24, and 26
Population: Full analysis set included all randomized participants who received at least 1 dose of study drug except 2 participants who received potentially defective IPs and were subsequently discontinued early because of IP issues. Here, 'N' (numbers of participants analyzed) signifies numbers of participants evaluable for this outcome measure; 'n' (number analyzed) signifies those participants who were evaluable at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Seltorexant | Change From Baseline in MADRS-6 Score Over Time | Week 26 | -9.1 score on a scale | Standard Deviation 8.97 |
| Seltorexant | Change From Baseline in MADRS-6 Score Over Time | Week 18 | -7.2 score on a scale | Standard Deviation 10.6 |
| Seltorexant | Change From Baseline in MADRS-6 Score Over Time | Week 2 | -4.4 score on a scale | Standard Deviation 6.76 |
| Seltorexant | Change From Baseline in MADRS-6 Score Over Time | Week 4 | -5.8 score on a scale | Standard Deviation 7.18 |
| Seltorexant | Change From Baseline in MADRS-6 Score Over Time | Week 6 | -6.7 score on a scale | Standard Deviation 7.69 |
| Seltorexant | Change From Baseline in MADRS-6 Score Over Time | Week 12 | -7.5 score on a scale | Standard Deviation 8.18 |
| Seltorexant | Change From Baseline in MADRS-6 Score Over Time | Week 24 | -9.1 score on a scale | Standard Deviation 9.4 |
| Quetiapine XR | Change From Baseline in MADRS-6 Score Over Time | Week 12 | -10.4 score on a scale | Standard Deviation 7.68 |
| Quetiapine XR | Change From Baseline in MADRS-6 Score Over Time | Week 6 | -7.5 score on a scale | Standard Deviation 6.95 |
| Quetiapine XR | Change From Baseline in MADRS-6 Score Over Time | Week 26 | -8.4 score on a scale | Standard Deviation 7.83 |
| Quetiapine XR | Change From Baseline in MADRS-6 Score Over Time | Week 24 | -10.3 score on a scale | Standard Deviation 8.59 |
| Quetiapine XR | Change From Baseline in MADRS-6 Score Over Time | Week 2 | -4.1 score on a scale | Standard Deviation 5.6 |
| Quetiapine XR | Change From Baseline in MADRS-6 Score Over Time | Week 18 | -9.2 score on a scale | Standard Deviation 8.62 |
| Quetiapine XR | Change From Baseline in MADRS-6 Score Over Time | Week 4 | -6.9 score on a scale | Standard Deviation 6.79 |
Secondary
Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline Insomnia Severity Index [ISI] Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score Less Than [<] 15) at Week 12
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition.
Time frame: Baseline and Week 12
Population: Full analysis set included all randomized participants who received at least 1 dose of study drug except 2 participants who received potentially defective IPs and were subsequently discontinued early because of the IP issues. Here, N (number of participants analyzed) signifies number of participants that were evaluable for this outcome measure and n (number analyzed) signifies those participants who were evaluable for specific categories.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Seltorexant | Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline Insomnia Severity Index [ISI] Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score Less Than [<] 15) at Week 12 | Baseline ISI score <15 | -10.4 score on a scale | Standard Deviation 12.68 |
| Seltorexant | Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline Insomnia Severity Index [ISI] Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score Less Than [<] 15) at Week 12 | Baseline ISI score >=15 | -13.4 score on a scale | Standard Deviation 10.73 |
| Quetiapine XR | Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline Insomnia Severity Index [ISI] Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score Less Than [<] 15) at Week 12 | Baseline ISI score <15 | -12.8 score on a scale | Standard Deviation 9.67 |
| Quetiapine XR | Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline Insomnia Severity Index [ISI] Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score Less Than [<] 15) at Week 12 | Baseline ISI score >=15 | -17.3 score on a scale | Standard Deviation 9.7 |
Secondary
Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISI Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score <15) at Week 18
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition.
Time frame: Baseline and Week 18
Population: Full analysis set included all randomized participants who received at least 1 dose of study drug except 2 participants who received potentially defective IPs and were subsequently discontinued early because of the IP issues. Here, N (number of participants analyzed) signifies number of participants that were evaluable for this outcome measure and n (number analyzed) signifies those participants who were evaluable for specific categories.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Seltorexant | Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISI Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score <15) at Week 18 | Baseline ISI score <15 | -13.9 score on a scale | Standard Deviation 16.66 |
| Seltorexant | Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISI Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score <15) at Week 18 | Baseline ISI score >=15 | -10.3 score on a scale | Standard Deviation 14.96 |
| Quetiapine XR | Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISI Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score <15) at Week 18 | Baseline ISI score <15 | -16.2 score on a scale | Standard Deviation 10.46 |
| Quetiapine XR | Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISI Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score <15) at Week 18 | Baseline ISI score >=15 | -12.9 score on a scale | Standard Deviation 11.58 |
Secondary
Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISIscore >=15) Versus Those Without Significant Insomnia (Baseline ISI Score 15) at Week 24
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition.
Time frame: Baseline and Week 24
Population: Full analysis set included all randomized participants who received at least 1 dose of study drug except 2 participants who received potentially defective IPs and were subsequently discontinued early because of the IP issues. Here, N (number of participants analyzed) signifies number of participants that were evaluable for this outcome measure. and n (number analyzed) signifies those participants who were evaluable for specific categories.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Seltorexant | Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISIscore >=15) Versus Those Without Significant Insomnia (Baseline ISI Score 15) at Week 24 | Baseline ISI score <15 | -14.3 score on a scale | Standard Deviation 14.47 |
| Seltorexant | Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISIscore >=15) Versus Those Without Significant Insomnia (Baseline ISI Score 15) at Week 24 | Baseline ISI score >=15 | -13.5 score on a scale | Standard Deviation 14.32 |
| Quetiapine XR | Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISIscore >=15) Versus Those Without Significant Insomnia (Baseline ISI Score 15) at Week 24 | Baseline ISI score >=15 | -15.4 score on a scale | Standard Deviation 11.76 |
| Quetiapine XR | Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISIscore >=15) Versus Those Without Significant Insomnia (Baseline ISI Score 15) at Week 24 | Baseline ISI score <15 | -15.6 score on a scale | Standard Deviation 8.78 |
Secondary
Change From Baseline in MADRS Total Score Over Time
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition.
Time frame: Baseline, Weeks 2, 4, 6, 12, 18, 24
Population: Full analysis set included all randomized participants who received at least 1 dose of study drug except 2 participants who received potentially defective IPs and were subsequently discontinued early because of the IP issues. Here, 'N' (numbers of participants analyzed) signifies numbers of participants evaluable for this outcome measure; 'n' (number analyzed) signifies those participants who were evaluable at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Seltorexant | Change From Baseline in MADRS Total Score Over Time | Week 24 | -13.8 score on a scale | Standard Deviation 14.13 |
| Seltorexant | Change From Baseline in MADRS Total Score Over Time | Week 2 | -6.7 score on a scale | Standard Deviation 9 |
| Seltorexant | Change From Baseline in MADRS Total Score Over Time | Week 4 | -8.7 score on a scale | Standard Deviation 9.71 |
| Seltorexant | Change From Baseline in MADRS Total Score Over Time | Week 6 | -9.9 score on a scale | Standard Deviation 9.98 |
| Seltorexant | Change From Baseline in MADRS Total Score Over Time | Week 12 | -12.3 score on a scale | Standard Deviation 11.41 |
| Seltorexant | Change From Baseline in MADRS Total Score Over Time | Week 18 | -11.7 score on a scale | Standard Deviation 15.48 |
| Quetiapine XR | Change From Baseline in MADRS Total Score Over Time | Week 12 | -15.6 score on a scale | Standard Deviation 9.8 |
| Quetiapine XR | Change From Baseline in MADRS Total Score Over Time | Week 24 | -15.4 score on a scale | Standard Deviation 10.57 |
| Quetiapine XR | Change From Baseline in MADRS Total Score Over Time | Week 6 | -11.4 score on a scale | Standard Deviation 9.4 |
| Quetiapine XR | Change From Baseline in MADRS Total Score Over Time | Week 2 | -6.4 score on a scale | Standard Deviation 8 |
| Quetiapine XR | Change From Baseline in MADRS Total Score Over Time | Week 18 | -14.1 score on a scale | Standard Deviation 11.41 |
| Quetiapine XR | Change From Baseline in MADRS Total Score Over Time | Week 4 | -10.8 score on a scale | Standard Deviation 9.6 |
Secondary
Change From Baseline in MADRS Total Score Over Time, by Mode Dose
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. Negative change in score indicates improvement.
Time frame: Baseline, Weeks 2, 4, 6, 12, 18, 24, and 26
Population: Full analysis set included all randomized participants who received at least 1 dose of study drug except 2 participants who received potentially defective IPs and were subsequently discontinued early because of IP issues. Here, 'N' (numbers of participants analyzed) signifies numbers of participants evaluable for this outcome measure; 'n' (number analyzed) signifies participants who were evaluable at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Seltorexant | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 26 | -16.3 score on a scale | Standard Deviation 7.52 |
| Seltorexant | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 4 | -7.7 score on a scale | Standard Deviation 8.05 |
| Seltorexant | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 2 | -7.3 score on a scale | Standard Deviation 7.28 |
| Seltorexant | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 24 | -14.9 score on a scale | Standard Deviation 7.93 |
| Seltorexant | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 6 | -9.1 score on a scale | Standard Deviation 9.26 |
| Seltorexant | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 12 | -11.8 score on a scale | Standard Deviation 9.34 |
| Seltorexant | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 18 | -12.8 score on a scale | Standard Deviation 9.98 |
| Quetiapine XR | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 12 | -5.3 score on a scale | Standard Deviation 6.69 |
| Quetiapine XR | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 18 | -3.8 score on a scale | Standard Deviation 9.64 |
| Quetiapine XR | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 24 | -5.2 score on a scale | Standard Deviation 8.38 |
| Quetiapine XR | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 26 | -9.3 score on a scale | Standard Deviation 8.98 |
| Quetiapine XR | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 4 | -4.4 score on a scale | Standard Deviation 6.25 |
| Quetiapine XR | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 6 | -5.2 score on a scale | Standard Deviation 6.26 |
| Quetiapine XR | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 2 | -2.4 score on a scale | Standard Deviation 5.66 |
| Quetiapine XR 150 mg | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 6 | -7.3 score on a scale | Standard Deviation 5.67 |
| Quetiapine XR 150 mg | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 26 | -8.3 score on a scale | Standard Deviation 7.1 |
| Quetiapine XR 150 mg | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 2 | -4.5 score on a scale | Standard Deviation 5.8 |
| Quetiapine XR 150 mg | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 4 | -6.9 score on a scale | Standard Deviation 6.99 |
| Quetiapine XR 150 mg | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 24 | -11.9 score on a scale | Standard Deviation 6.06 |
| Quetiapine XR 150 mg | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 12 | -12.5 score on a scale | Standard Deviation 6.87 |
| Quetiapine XR 150 mg | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 18 | -6.0 score on a scale | Standard Deviation 8.26 |
| Quetiapine XR 300 mg | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 26 | -8.6 score on a scale | Standard Deviation 8.45 |
| Quetiapine XR 300 mg | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 4 | -6.9 score on a scale | Standard Deviation 6.79 |
| Quetiapine XR 300 mg | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 2 | -3.6 score on a scale | Standard Deviation 5.49 |
| Quetiapine XR 300 mg | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 6 | -7.6 score on a scale | Standard Deviation 7.82 |
| Quetiapine XR 300 mg | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 18 | -10.5 score on a scale | Standard Deviation 8.61 |
| Quetiapine XR 300 mg | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 24 | -9.7 score on a scale | Standard Deviation 9.53 |
| Quetiapine XR 300 mg | Change From Baseline in MADRS Total Score Over Time, by Mode Dose | Week 12 | -9.3 score on a scale | Standard Deviation 7.99 |
Secondary
Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form 8a at Weeks 12 and 24
The PROMIS-SD Short Form 8a subscale consists of a static 8 item questionnaire. It assesses the concepts of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items) and worrying about sleep (1 item). Responses to each of the 8 items range from 1 to 5, and the range of possible summed raw scores is 8 to 40. Higher scores on the PROMIS-SD indicate more of the concept measured (disturbed sleep). Negative change in score indicates improvement.
Time frame: Baseline, Weeks 12 and 24
Population: Full analysis set included all randomized participants who received at least 1 dose of study drug except 2 participants who received potentially defective IPs and were subsequently discontinued early because of the IP issues. Here, 'N' (numbers of participants analyzed) signifies numbers of participants evaluable for this outcome measure; 'n' (number analyzed) signifies those participants who were evaluable at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Seltorexant | Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form 8a at Weeks 12 and 24 | Week 12 | -8.22 units on a scale | Standard Deviation 10.073 |
| Seltorexant | Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form 8a at Weeks 12 and 24 | Week 24 | -11.45 units on a scale | Standard Deviation 11.722 |
| Quetiapine XR | Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form 8a at Weeks 12 and 24 | Week 12 | -11.87 units on a scale | Standard Deviation 10.717 |
| Quetiapine XR | Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form 8a at Weeks 12 and 24 | Week 24 | -12.91 units on a scale | Standard Deviation 7.878 |
Secondary
Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Related Impairment (PROMIS-SRI) Short Form 8a at Weeks 12 and 24
The PROMIS-SRI Short Form 8a subscale consists of a static 8 item questionnaire and use five-point likert scale to capture the participant's impressions. It assesses sleep-related impairment over the past 7 days. Responses to each of the 8 items range from 1 (less impairment) to 5 (more impairment), and the range of possible summed raw scores is 8 to 40. Lower scores indicate less sleep related impairment. Negative change in score indicates improvement.
Time frame: Baseline, Weeks 12 and 24
Population: Full analysis set included all randomized participants who received at least 1 dose of study drug except 2 participants who received potentially defective IPs and were subsequently discontinued early because of the IP issues. Here, 'N' (numbers of participants analyzed) signifies numbers of participants evaluable for this outcome measure; 'n' (number analyzed) signifies those participants who were evaluable at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Seltorexant | Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Related Impairment (PROMIS-SRI) Short Form 8a at Weeks 12 and 24 | Week 12 | -7.25 units on a scale | Standard Deviation 9.449 |
| Seltorexant | Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Related Impairment (PROMIS-SRI) Short Form 8a at Weeks 12 and 24 | Week 24 | -11.02 units on a scale | Standard Deviation 11.061 |
| Quetiapine XR | Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Related Impairment (PROMIS-SRI) Short Form 8a at Weeks 12 and 24 | Week 12 | -9.09 units on a scale | Standard Deviation 7.992 |
| Quetiapine XR | Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Related Impairment (PROMIS-SRI) Short Form 8a at Weeks 12 and 24 | Week 24 | -10.74 units on a scale | Standard Deviation 6.97 |
Secondary
Change From Baseline in Quality of Life in Depression Scale (QLDS) Score at Weeks 12 and 24
The QLDS is a disease specific patient-reported outcome (PRO) designed to assess health related quality of life in participants with major depressive disorder (MDD). The instrument has a recall period of at the present time, contains 34-items with true/not true response options. Each statement on the QLDS is given a score of 1 (adverse quality of life) or 0 good quality of life. All item scores are summed to give a total score that ranges from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition. Negative change indicates improvement.
Time frame: Baseline, Weeks 12 and 24
Population: Full analysis set included all randomized participants who received at least 1 dose of study drug except 2 participants who received potentially defective IPs and were subsequently discontinued early because of the IP issues. Here, 'N' (numbers of participants analyzed) signifies numbers of participants evaluable for this outcome measure; 'n' (number analyzed) signifies those participants who were evaluable at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Seltorexant | Change From Baseline in Quality of Life in Depression Scale (QLDS) Score at Weeks 12 and 24 | Week 12 | -8.1 units on a scale | Standard Deviation 9.2 |
| Seltorexant | Change From Baseline in Quality of Life in Depression Scale (QLDS) Score at Weeks 12 and 24 | Week 24 | -9.5 units on a scale | Standard Deviation 10.32 |
| Quetiapine XR | Change From Baseline in Quality of Life in Depression Scale (QLDS) Score at Weeks 12 and 24 | Week 12 | -8.3 units on a scale | Standard Deviation 8.68 |
| Quetiapine XR | Change From Baseline in Quality of Life in Depression Scale (QLDS) Score at Weeks 12 and 24 | Week 24 | -9.9 units on a scale | Standard Deviation 10.43 |
Secondary
Change From Baseline in Salivary Cortisol Levels as Measured at Home Upon Awakening and During the Evening at Weeks 6 and 24
Change from baseline in salivary cortisol levels as measured upon awakening and at home during the evening at Weeks 6 and 24 were reported.
Time frame: Baseline, Weeks 6 and 24
Population: The biomarker analysis set included all randomized participants who received at least 1 dose of study drug during the double-blind (DB) treatment phase and had biomarker data at baseline. Here, 'N' (numbers of participants analyzed) signifies numbers of participants evaluable for this outcome measure; 'n' (number analyzed) signifies those participants who were evaluable at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Seltorexant | Change From Baseline in Salivary Cortisol Levels as Measured at Home Upon Awakening and During the Evening at Weeks 6 and 24 | Awakening: Week 6 | 1.3 nanomoles per liter (nmol/L) | Standard Deviation 9.07 |
| Seltorexant | Change From Baseline in Salivary Cortisol Levels as Measured at Home Upon Awakening and During the Evening at Weeks 6 and 24 | Awakening: Week 24 | 1.4 nanomoles per liter (nmol/L) | Standard Deviation 9.42 |
| Seltorexant | Change From Baseline in Salivary Cortisol Levels as Measured at Home Upon Awakening and During the Evening at Weeks 6 and 24 | Evening: Week 6 | -0.7 nanomoles per liter (nmol/L) | Standard Deviation 4.59 |
| Seltorexant | Change From Baseline in Salivary Cortisol Levels as Measured at Home Upon Awakening and During the Evening at Weeks 6 and 24 | Evening: Week 24 | 1.4 nanomoles per liter (nmol/L) | Standard Deviation 6.85 |
| Quetiapine XR | Change From Baseline in Salivary Cortisol Levels as Measured at Home Upon Awakening and During the Evening at Weeks 6 and 24 | Evening: Week 24 | 0.9 nanomoles per liter (nmol/L) | Standard Deviation 2.73 |
| Quetiapine XR | Change From Baseline in Salivary Cortisol Levels as Measured at Home Upon Awakening and During the Evening at Weeks 6 and 24 | Awakening: Week 6 | -2.8 nanomoles per liter (nmol/L) | Standard Deviation 8.27 |
| Quetiapine XR | Change From Baseline in Salivary Cortisol Levels as Measured at Home Upon Awakening and During the Evening at Weeks 6 and 24 | Evening: Week 6 | 0.5 nanomoles per liter (nmol/L) | Standard Deviation 5.96 |
| Quetiapine XR | Change From Baseline in Salivary Cortisol Levels as Measured at Home Upon Awakening and During the Evening at Weeks 6 and 24 | Awakening: Week 24 | -1.7 nanomoles per liter (nmol/L) | Standard Deviation 6.86 |
Secondary
Change From Baseline in Symbol Digit Modalities Test (SDMT) at Weeks 6, 12, and 24
SDMT is a widely used, paper-and-pencil assessment of complex scanning and visual tracking, requiring elements of attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The test is viewed as a robust screening test for adult neuropsychological impairment and is sensitive to impairments in cognitive function associated with MDD. The SDMT measured the time to pair abstract symbols with specific numbers. The test included a coding key consisting of 9 abstract symbols, each paired with a number ranging from 1 to 9. Following the key, the participant was presented with randomly ordered symbols and was required to write the number corresponding to each symbol as fast as possible. The number of correct substitutions within 90 seconds was recorded and total score derived from the total number of correct responses with a minimum possible score of 0 and maximum of 110 where high scores indicate better outcome. Positive change in score indicates improvement.
Time frame: Baseline, Weeks 6, 12, and 24
Population: Full analysis set included all randomized participants who received at least 1 dose of study drug except 2 participants who received potentially defective IPs and were subsequently discontinued early because of the IP issues. Here, 'N' (numbers of participants analyzed) signifies numbers of participants evaluable for this outcome measure; 'n' (number analyzed) signifies those participants who were evaluable at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Seltorexant | Change From Baseline in Symbol Digit Modalities Test (SDMT) at Weeks 6, 12, and 24 | Week 6 | 5.0 units on a scale | Standard Deviation 14.45 |
| Seltorexant | Change From Baseline in Symbol Digit Modalities Test (SDMT) at Weeks 6, 12, and 24 | Week 12 | 5.5 units on a scale | Standard Deviation 17.61 |
| Seltorexant | Change From Baseline in Symbol Digit Modalities Test (SDMT) at Weeks 6, 12, and 24 | Week 24 | 4.7 units on a scale | Standard Deviation 18.78 |
| Quetiapine XR | Change From Baseline in Symbol Digit Modalities Test (SDMT) at Weeks 6, 12, and 24 | Week 12 | 0.1 units on a scale | Standard Deviation 14.07 |
| Quetiapine XR | Change From Baseline in Symbol Digit Modalities Test (SDMT) at Weeks 6, 12, and 24 | Week 24 | 0.0 units on a scale | Standard Deviation 9.83 |
| Quetiapine XR | Change From Baseline in Symbol Digit Modalities Test (SDMT) at Weeks 6, 12, and 24 | Week 6 | -2.9 units on a scale | Standard Deviation 11.72 |
Secondary
Change From Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Score at Weeks 12 and 24
The SMDDS assesses participant-reported symptoms associated with MDD. This 16-item instrument has a 7-day recall period, and participants respond to each question using a rating scale between 0 (Not at all or Never) to 4 (Extremely or Always). Before summing the items to create a total score, item 11 (how often did you have a poor appetite) and item 12 (how often did you over eat) are combined into a single score by selecting the highest severity on either item. The total score is then created by summing the responses on the 15 items. The total score ranges from 0 to 60 with a higher score indicating more severe depressive symptomatology. Negative change in score indicates improvement.
Time frame: Baseline, Weeks 12 and 24
Population: Full analysis set included all randomized participants who received at least 1 dose of study drug except 2 participants who received potentially defective IPs and were subsequently discontinued early because of the IP issues. Here, 'N' (numbers of participants analyzed) signifies numbers of participants evaluable for this outcome measure; 'n' (number analyzed) signifies those participants who were evaluable at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Seltorexant | Change From Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Score at Weeks 12 and 24 | Week 12 | -13.9 units on a scale | Standard Deviation 10.92 |
| Seltorexant | Change From Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Score at Weeks 12 and 24 | Week 24 | -15.6 units on a scale | Standard Deviation 13.07 |
| Quetiapine XR | Change From Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Score at Weeks 12 and 24 | Week 24 | -19.6 units on a scale | Standard Deviation 11.59 |
| Quetiapine XR | Change From Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Score at Weeks 12 and 24 | Week 12 | -15.7 units on a scale | Standard Deviation 11.16 |
Secondary
Change From Baseline in the Clinical Global Impression-Severity (CGI-S) Scale Score at Weeks 12 and 24
The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S is a 7-point global assessment scale that measures the clinician's impression of the severity of illness exhibited by a participant, rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. Higher scores indicate worsening. Negative change in score indicates improvement.
Time frame: Baseline, Weeks 12 and 24
Population: Full analysis set included all randomized participants who received at least 1 dose of study drug except 2 participants who received potentially defective IPs and were subsequently discontinued early because of the IP issues. Here, 'N' (numbers of participants analyzed) signifies numbers of participants evaluable for this outcome measure; 'n' (number analyzed) signifies those participants who were evaluable at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Seltorexant | Change From Baseline in the Clinical Global Impression-Severity (CGI-S) Scale Score at Weeks 12 and 24 | Week 12 | -1.2 units on a scale | Standard Deviation 1.39 |
| Seltorexant | Change From Baseline in the Clinical Global Impression-Severity (CGI-S) Scale Score at Weeks 12 and 24 | Week 24 | -1.4 units on a scale | Standard Deviation 1.65 |
| Quetiapine XR | Change From Baseline in the Clinical Global Impression-Severity (CGI-S) Scale Score at Weeks 12 and 24 | Week 12 | -1.7 units on a scale | Standard Deviation 1.23 |
| Quetiapine XR | Change From Baseline in the Clinical Global Impression-Severity (CGI-S) Scale Score at Weeks 12 and 24 | Week 24 | -1.7 units on a scale | Standard Deviation 1.1 |
Secondary
Change From Baseline in the Hamilton Anxiety Rating Scale (HAM-A) Total Score at Weeks 12, 18, and 24
HAM-A is a 14-item scale designed to measure anxiety in individuals. Each question reflects a symptom of anxiety and physical as well as mental symptoms are represented. Each of the 14-items in the scale is scored on a 5-point scale, ranging from 0 (a complete lack of that symptom) to 4 (a very severe show of anxiety with that symptom). The total score ranges from 0 to 56 which is calculated by adding the scores of all 14 items, where 0-13 indicates normal range, 14-17 indicates mild severity, 18 -24: mild to moderate severity, 25 -30: moderate to severe, and \>=31: severe. Higher score indicates worsening. Negative change in score indicates improvement.
Time frame: Baseline, Weeks 12, 18, and 24
Population: Full analysis set included all randomized participants who received at least 1 dose of study drug except 2 participants who received potentially defective IPs and were subsequently discontinued early because of the IP issues. Here, 'N' (numbers of participants analyzed) signifies numbers of participants evaluable for this outcome measure; 'n' (number analyzed) signifies those participants who were evaluable at specified timepoints for specific timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Seltorexant | Change From Baseline in the Hamilton Anxiety Rating Scale (HAM-A) Total Score at Weeks 12, 18, and 24 | Week 12 | -8.7 units on a scale | Standard Deviation 6.05 |
| Seltorexant | Change From Baseline in the Hamilton Anxiety Rating Scale (HAM-A) Total Score at Weeks 12, 18, and 24 | Week 24 | -10.9 units on a scale | Standard Deviation 6.55 |
| Seltorexant | Change From Baseline in the Hamilton Anxiety Rating Scale (HAM-A) Total Score at Weeks 12, 18, and 24 | Week 18 | -8.5 units on a scale | Standard Deviation 6.66 |
| Quetiapine XR | Change From Baseline in the Hamilton Anxiety Rating Scale (HAM-A) Total Score at Weeks 12, 18, and 24 | Week 18 | -10.0 units on a scale | Standard Deviation 5.69 |
| Quetiapine XR | Change From Baseline in the Hamilton Anxiety Rating Scale (HAM-A) Total Score at Weeks 12, 18, and 24 | Week 24 | -9.5 units on a scale | Standard Deviation 7.26 |
| Quetiapine XR | Change From Baseline in the Hamilton Anxiety Rating Scale (HAM-A) Total Score at Weeks 12, 18, and 24 | Week 12 | -6.6 units on a scale | Standard Deviation 6.75 |
Secondary
Change From Baseline in the Patient Global Impression Severity (PGI-S) Scale Score at Weeks 12 and 24
The PGI-S is a self-report scale to measure severity of illness (1=none, 2=mild, 3=moderate, 4=severe). Higher score indicates more illness severity. Negative change in score indicates improvement.
Time frame: Baseline, Weeks 12 and 24
Population: Full analysis set included all randomized participants who received at least 1 dose of study drug except 2 participants who received potentially defective IPs and were subsequently discontinued early because of the IP issues. Here, 'N' (numbers of participants analyzed) signifies numbers of participants evaluable for this outcome measure; 'n' (number analyzed) signifies those participants who were evaluable at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Seltorexant | Change From Baseline in the Patient Global Impression Severity (PGI-S) Scale Score at Weeks 12 and 24 | Week 12 | -1.0 units on a scale | Standard Deviation 1.07 |
| Seltorexant | Change From Baseline in the Patient Global Impression Severity (PGI-S) Scale Score at Weeks 12 and 24 | Week 24 | -1.2 units on a scale | Standard Deviation 1.1 |
| Quetiapine XR | Change From Baseline in the Patient Global Impression Severity (PGI-S) Scale Score at Weeks 12 and 24 | Week 12 | -1.1 units on a scale | Standard Deviation 1.02 |
| Quetiapine XR | Change From Baseline in the Patient Global Impression Severity (PGI-S) Scale Score at Weeks 12 and 24 | Week 24 | -1.5 units on a scale | Standard Deviation 1.09 |
Secondary
Change From Baseline in Trail Making Test - Part B (TMT-Part B) at Weeks 6, 12, and 24
The TMT-Part B measures divided attention and executive function (tracking and sequencing). The participant is instructed to draw a line to connect a set of 25 consecutively numbered and lettered circles, alternating sequentially between numbers and letters (that is, 1 A 2 B). The participant is instructed to work as quickly as possible while still maintaining accuracy. Score included time (seconds) to completion and number of errors in performing the test which ranges from 0 (no errors) to 25 (more errors), where shorter time and less number of errors indicates better performance. The TMT-Part B is sensitive to cognitive decline associated with MDD. Negative change in score indicates improvement.
Time frame: Baseline, Weeks 6, 12, and 24
Population: Full analysis set included all randomized participants who received at least 1 dose of study drug except 2 participants who received potentially defective IPs and were subsequently discontinued early because of the IP issues. Here, 'N' (numbers of participants analyzed) signifies numbers of participants evaluable for this outcome measure; 'n' (number analyzed) signifies those participants who were evaluable at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Seltorexant | Change From Baseline in Trail Making Test - Part B (TMT-Part B) at Weeks 6, 12, and 24 | Week 6 | 0.4 units on a scale | Standard Deviation 3.26 |
| Seltorexant | Change From Baseline in Trail Making Test - Part B (TMT-Part B) at Weeks 6, 12, and 24 | Week 12 | 0.2 units on a scale | Standard Deviation 3.39 |
| Seltorexant | Change From Baseline in Trail Making Test - Part B (TMT-Part B) at Weeks 6, 12, and 24 | Week 24 | 0.5 units on a scale | Standard Deviation 4.54 |
| Quetiapine XR | Change From Baseline in Trail Making Test - Part B (TMT-Part B) at Weeks 6, 12, and 24 | Week 12 | 0.6 units on a scale | Standard Deviation 2.93 |
| Quetiapine XR | Change From Baseline in Trail Making Test - Part B (TMT-Part B) at Weeks 6, 12, and 24 | Week 24 | -0.3 units on a scale | Standard Deviation 1.54 |
| Quetiapine XR | Change From Baseline in Trail Making Test - Part B (TMT-Part B) at Weeks 6, 12, and 24 | Week 6 | 0.0 units on a scale | Standard Deviation 2.59 |
Secondary
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters
Percentage of participants with abnormalities in clinical laboratory parameters were reported.
Time frame: Up to 24 weeks
Population: The safety analysis set included all randomized participants who received at least 1 dose of study drug including the 2 participants who received the potentially defective IP.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Seltorexant | Percentage of Participants With Abnormalities in Clinical Laboratory Parameters | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Abnormalities in Clinical Laboratory Parameters | 0 percentage of participants |
Secondary
Percentage of Participants With Abnormalities in Electrocardiogram (ECG) Parameters
Percentage of participants with abnormalities in ECG parameters were reported.
Time frame: Up to 24 weeks
Population: The safety analysis set included all randomized participants who received at least 1 dose of study drug including the 2 participants who received the potentially defective IP.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Seltorexant | Percentage of Participants With Abnormalities in Electrocardiogram (ECG) Parameters | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Abnormalities in Electrocardiogram (ECG) Parameters | 0 percentage of participants |
Secondary
Percentage of Participants With Abnormalities in Vital Sign Parameters
Percentage of participants with abnormalities in vital sign parameters (pulse, supine and standing blood pressure \[systolic and diastolic\], body temperature, and body weight) were reported. Abnormally low values for parameters included pulse (beats per minute)- decrease value from baseline (\>=) 15 to \<=50; Systolic Blood Pressure (BP) (mmHg \[Millimeter of mercury\])- decrease value from baseline \>=20 to \<=90; Diastolic BP- decrease value from baseline \>=15 to \<=50; weight (Kilogram\[Kg\])- decrease from baseline of \>=7%; Body temperature (Celsius \[C\])- \<35.5. Abnormally high values for parameters included pulse- increase value from baseline \>=15 to \>=100; Systolic BP(mmHg)- increase from baseline of \>=20 to \>=180; Diastolic BP- increase value from baseline \>=15 to \>=105; weight(Kg)- increase from baseline of \>=7%; body temperature (C)- \>37.5.
Time frame: Up to 24 weeks
Population: The safety analysis set included all randomized participants who received at least 1 dose of study drug including the 2 participants who received the potentially defective IP. Here, 'N' (numbers of participants analyzed) signifies numbers of participants evaluable for this outcome measure; 'n' (number analyzed) signifies those participants who were evaluable for specified categories.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Seltorexant | Percentage of Participants With Abnormalities in Vital Sign Parameters | Standing Pulse Rate: Abnormally high | 2.0 percentage of participants |
| Seltorexant | Percentage of Participants With Abnormalities in Vital Sign Parameters | Standing Systolic Blood Pressure: Abnormally high | 0 percentage of participants |
| Seltorexant | Percentage of Participants With Abnormalities in Vital Sign Parameters | Temperature: Abnormally low | 0 percentage of participants |
| Seltorexant | Percentage of Participants With Abnormalities in Vital Sign Parameters | Supine Systolic Blood Pressure: Abnormally high | 0 percentage of participants |
| Seltorexant | Percentage of Participants With Abnormalities in Vital Sign Parameters | Temperature: Abnormally high | 6.0 percentage of participants |
| Seltorexant | Percentage of Participants With Abnormalities in Vital Sign Parameters | Weight: Abnormally low | 4.3 percentage of participants |
| Seltorexant | Percentage of Participants With Abnormalities in Vital Sign Parameters | Supine Diastolic Blood Pressure: Abnormally low | 0 percentage of participants |
| Seltorexant | Percentage of Participants With Abnormalities in Vital Sign Parameters | Weight: Abnormally high | 4.3 percentage of participants |
| Seltorexant | Percentage of Participants With Abnormalities in Vital Sign Parameters | Supine Systolic Blood Pressure: Abnormally low | 0 percentage of participants |
| Seltorexant | Percentage of Participants With Abnormalities in Vital Sign Parameters | Supine Pulse Rate: Abnormally low | 0 percentage of participants |
| Seltorexant | Percentage of Participants With Abnormalities in Vital Sign Parameters | Supine Diastolic Blood Pressure: Abnormally high | 0 percentage of participants |
| Seltorexant | Percentage of Participants With Abnormalities in Vital Sign Parameters | Supine Pulse Rate: Abnormally high | 2.0 percentage of participants |
| Seltorexant | Percentage of Participants With Abnormalities in Vital Sign Parameters | Standing Systolic Blood Pressure: Abnormally low | 0 percentage of participants |
| Seltorexant | Percentage of Participants With Abnormalities in Vital Sign Parameters | Standing Diastolic Blood Pressure: Abnormally low | 0 percentage of participants |
| Seltorexant | Percentage of Participants With Abnormalities in Vital Sign Parameters | Standing Diastolic Blood Pressure: Abnormally high | 2.0 percentage of participants |
| Seltorexant | Percentage of Participants With Abnormalities in Vital Sign Parameters | Standing Pulse Rate: Abnormally low | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Abnormalities in Vital Sign Parameters | Temperature: Abnormally high | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Abnormalities in Vital Sign Parameters | Standing Pulse Rate: Abnormally high | 5.9 percentage of participants |
| Quetiapine XR | Percentage of Participants With Abnormalities in Vital Sign Parameters | Supine Systolic Blood Pressure: Abnormally low | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Abnormalities in Vital Sign Parameters | Supine Systolic Blood Pressure: Abnormally high | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Abnormalities in Vital Sign Parameters | Standing Systolic Blood Pressure: Abnormally low | 2.0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Abnormalities in Vital Sign Parameters | Standing Systolic Blood Pressure: Abnormally high | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Abnormalities in Vital Sign Parameters | Supine Diastolic Blood Pressure: Abnormally low | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Abnormalities in Vital Sign Parameters | Supine Diastolic Blood Pressure: Abnormally high | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Abnormalities in Vital Sign Parameters | Standing Diastolic Blood Pressure: Abnormally low | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Abnormalities in Vital Sign Parameters | Standing Diastolic Blood Pressure: Abnormally high | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Abnormalities in Vital Sign Parameters | Temperature: Abnormally low | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Abnormalities in Vital Sign Parameters | Weight: Abnormally low | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Abnormalities in Vital Sign Parameters | Weight: Abnormally high | 8.5 percentage of participants |
| Quetiapine XR | Percentage of Participants With Abnormalities in Vital Sign Parameters | Supine Pulse Rate: Abnormally low | 2.0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Abnormalities in Vital Sign Parameters | Supine Pulse Rate: Abnormally high | 3.9 percentage of participants |
| Quetiapine XR | Percentage of Participants With Abnormalities in Vital Sign Parameters | Standing Pulse Rate: Abnormally low | 0 percentage of participants |
Secondary
Percentage of Participants With Clinically Relevant Changes in Extrapyramidal Symptoms Assessed by the Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Score
The ESRS-A is an abbreviated manualized version of the ESRS, a semi-structured interview that rates parkinsonian symptoms, dystonia, dyskinesias, and akathisia over the previous 7 days. The ratings include a motor examination for rigidity, tremor, reduced facial expression or speech, impaired gait/posture, postural instability, and bradykinesia/hypokinesia. Twenty-four individual items are rated on a 6-point scale: 0=Absent, 1=Minimal, 2=Mild, 3=Moderate, 4=Severe, or 5=Extreme. Frequency is included as an index of severity.
Time frame: Up to Endpoint (Up to 24 weeks)
Population: The safety analysis set included all randomized participants who received at least 1 dose of study drug including the 2 participants who received the potentially defective IP. End Point (DB) is the last post baseline observation during the double blind phase.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Seltorexant | Percentage of Participants With Clinically Relevant Changes in Extrapyramidal Symptoms Assessed by the Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Score | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Clinically Relevant Changes in Extrapyramidal Symptoms Assessed by the Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Score | 0 percentage of participants |
Secondary
Percentage of Participants With Sexual Dysfunction as Determined by Arizona Sexual Experiences Scale (ASEX) Total Score
Sexual dysfunction is defined as an ASEX total score of 19 or greater, or a score of 5 or greater on any item, or a score of 4 or greater on any 3 items. ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Each of the 5 items is rated on a 6-point Likert scale, ranging from 1 to 6. The 5 items are summed to create a total score, ranging from 5 to 30, with the higher scores indicating more sexual dysfunction.
Time frame: Up to Endpoint (Up to 24 weeks)
Population: The safety analysis set included all randomized participants who received at least 1 dose of study drug including the 2 participants who received the potentially defective IP. Here, 'N' (numbers of participants analyzed) signifies numbers of participants evaluable for this outcome measure. End point double-blind (DB) is the last post baseline observation during the double blind phase.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Seltorexant | Percentage of Participants With Sexual Dysfunction as Determined by Arizona Sexual Experiences Scale (ASEX) Total Score | 64.3 percentage of participants |
| Quetiapine XR | Percentage of Participants With Sexual Dysfunction as Determined by Arizona Sexual Experiences Scale (ASEX) Total Score | 75.6 percentage of participants |
Secondary
Percentage of Participants With Shifts in Fasting Blood Glucose From Borderline to High
Percentage of participants with shifts in fasting blood glucose from borderline to high (\>=100 to \<126 mg/dL at baseline to \>=126 mg/dL at any post-baseline assessment) were reported.
Time frame: Up to Week 24
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug including the 2 participants who received the potentially defective IP. Here, 'N' (numbers of participants analyzed) signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Seltorexant | Percentage of Participants With Shifts in Fasting Blood Glucose From Borderline to High | 9.1 percentage of participants |
| Quetiapine XR | Percentage of Participants With Shifts in Fasting Blood Glucose From Borderline to High | 25.0 percentage of participants |
Secondary
Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to Borderline
Percentage of participants with shifts in fasting blood glucose from normal to borderline (\<100 mg/dL at baseline to between \>=100 and \<126 mg/dL at any post-baseline assessment) were reported.
Time frame: Up to Week 24
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug including the 2 participants who received the potentially defective IP. Here, 'N' (numbers of participants analyzed) signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Seltorexant | Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to Borderline | 38.7 percentage of participants |
| Quetiapine XR | Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to Borderline | 36.0 percentage of participants |
Secondary
Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to High
Percentage of participants with shifts in fasting blood glucose from normal to high (\<100 mg/dL at baseline to \>=126 mg/dL at any post-baseline assessment) were reported.
Time frame: Up to Week 24
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug including the 2 participants who received the potentially defective IP. Here, 'N' (numbers of participants analyzed) signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Seltorexant | Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to High | 3.2 percentage of participants |
| Quetiapine XR | Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to High | 4.0 percentage of participants |
Secondary
Percentage of Participants With Shifts in Triglycerides From Borderline to High
Percentage of participants with shifts in triglycerides from borderline to high (\>=150 to \<200 mg/dL at baseline to \>=200 mg/dL at any post-baseline assessment) were reported.
Time frame: Up to Week 24
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug including the 2 participants who received the potentially defective IP. Here, 'N' (numbers of participants analyzed) signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Seltorexant | Percentage of Participants With Shifts in Triglycerides From Borderline to High | 25.0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Shifts in Triglycerides From Borderline to High | 37.5 percentage of participants |
Secondary
Percentage of Participants With Shifts in Triglycerides From Borderline to Very High
Percentage of participants with shifts in triglycerides from borderline to very high (\>=150 mg/dL to \<200 mg/dL at baseline to \>=500 mg/dL at any post-baseline assessment) were reported.
Time frame: Up to Week 24
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug including the 2 participants who received the potentially defective IP. Here, 'N' (numbers of participants analyzed) signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Seltorexant | Percentage of Participants With Shifts in Triglycerides From Borderline to Very High | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Shifts in Triglycerides From Borderline to Very High | 0 percentage of participants |
Secondary
Percentage of Participants With Shifts in Triglycerides From High to Very High
Percentage of participants with shifts in triglycerides from high to very high (\>=200 mg/dL to \<500 mg/dL at baseline to \>=500 mg/dL at any post-baseline assessment) were reported.
Time frame: Up to Week 24
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug including the 2 participants who received the potentially defective IP. Here, 'N' (numbers of participants analyzed) signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Seltorexant | Percentage of Participants With Shifts in Triglycerides From High to Very High | 16.7 percentage of participants |
| Quetiapine XR | Percentage of Participants With Shifts in Triglycerides From High to Very High | 0 percentage of participants |
Secondary
Percentage of Participants With Shifts in Triglycerides From Normal to High
Percentage of participants with shifts in triglycerides from normal to high (\<150 milligrams per deciliter \[mg/dL\] at baseline to \>=200 mg/dL at any post-baseline assessment) were reported.
Time frame: Up to Week 24
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug including the 2 participants who received the potentially defective IP. Here, 'N' (numbers of participants analyzed) signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Seltorexant | Percentage of Participants With Shifts in Triglycerides From Normal to High | 7.1 percentage of participants |
| Quetiapine XR | Percentage of Participants With Shifts in Triglycerides From Normal to High | 13.6 percentage of participants |
Secondary
Percentage of Participants With Shifts in Triglycerides From Normal to Very High
Percentage of participants with shifts in triglycerides from normal to very high (\<150 mg/dL at baseline to \>=500 mg/dL at any post-baseline assessment) were reported.
Time frame: Up to Week 24
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug including the 2 participants who received the potentially defective IP. Here, 'N' (numbers of participants analyzed) signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Seltorexant | Percentage of Participants With Shifts in Triglycerides From Normal to Very High | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Shifts in Triglycerides From Normal to Very High | 0 percentage of participants |
Secondary
Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score
C-SSRS is a clinician-rated instrument that reports severity and frequency of suicide-related ideation and behaviors. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (non-specific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 6 (preparatory acts or behavior), 7 (aborted attempt), 8 (interrupted attempt), 9 (actual attempt \[non-fatal\]), and 10 (completed suicide \[only applicable for post baseline\]). Minimum total score 0, maximum total score 10; higher total scores indicate more suicidal ideation and/or suicidal behavior. If no events qualify for score of 1 to 10, score of 0 was assigned (0= no event that can be assessed on the basis of C-SSRS). Higher scores indicate greater severity.
Time frame: Up to Endpoint (Up to 24 weeks)
Population: The safety analysis set included all randomized participants who received at least 1 dose of study drug including the 2 participants who received the potentially defective IP. End Point (DB) is the last post baseline observation during the double blind phase.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Seltorexant | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 0=No Event | 100 percentage of participants |
| Seltorexant | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 6 = Preparatory Acts or Behavior | 0 percentage of participants |
| Seltorexant | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 7 = Aborted Attempt | 0 percentage of participants |
| Seltorexant | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 9 = Actual Attempt | 0 percentage of participants |
| Seltorexant | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 10 = Completed Suicide | 0 percentage of participants |
| Seltorexant | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 3 = Suicidal Ideation Without Plan and Intent | 0 percentage of participants |
| Seltorexant | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 4 = Suicidal Ideation Intent to Act Without Plan | 0 percentage of participants |
| Seltorexant | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 5 = Suicidal Ideation With Plan and Intent | 0 percentage of participants |
| Seltorexant | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 8 = Interrupted Attempt | 0 percentage of participants |
| Seltorexant | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 1=Wish to be Dead | 0 percentage of participants |
| Seltorexant | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 2 = Non-Specific Active Suicidal Thoughts | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 10 = Completed Suicide | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 0=No Event | 100 percentage of participants |
| Quetiapine XR | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 2 = Non-Specific Active Suicidal Thoughts | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 3 = Suicidal Ideation Without Plan and Intent | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 4 = Suicidal Ideation Intent to Act Without Plan | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 6 = Preparatory Acts or Behavior | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 7 = Aborted Attempt | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 8 = Interrupted Attempt | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 1=Wish to be Dead | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 9 = Actual Attempt | 0 percentage of participants |
| Quetiapine XR | Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score | 5 = Suicidal Ideation With Plan and Intent | 0 percentage of participants |
Secondary
Percentage of Participants With Sustained Remission up to Week 24
Remission is defined as Montgomery-Asberg Depression Rating Scale (MADRS) total score of less than or equal to (\<=) 12. A participant was defined as having achieved sustained remission if the MADRS total score was ≤12 at Week 12 and was sustained at Weeks 18 and 24. Participants with missing values at a given time point were imputed as non-evaluable for remission. MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition.
Time frame: Up to Week 24
Population: Full analysis set included all randomized participants who received at least 1 dose of study drug except 2 participants who received potentially defective IPs and were subsequently discontinued early because of the IP issues. Here, N (number of participants analyzed) signifies number of participants that were evaluable for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Seltorexant | Percentage of Participants With Sustained Remission up to Week 24 | 13.2 percentage of participants |
| Quetiapine XR | Percentage of Participants With Sustained Remission up to Week 24 | 19.4 percentage of participants |
Secondary
Percentage of Participants With Sustained Response up to Week 24
A participant was defined as having achieved a sustained response if there was at least a 50% improvement from baseline in the MADRS total score at Week 12, and that response was maintained at Week 18 and Week 24. Participants who did not meet such criterion were considered as non-sustained responders. MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition.
Time frame: Up to Week 24
Population: Full analysis set included all randomized participants who received at least 1 dose of study drug except 2 participants who received potentially defective IPs and were subsequently discontinued early because of the IP issues. Here, N (number of participants analyzed) signifies number of participants that were evaluable for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Seltorexant | Percentage of Participants With Sustained Response up to Week 24 | 13.2 percentage of participants |
| Quetiapine XR | Percentage of Participants With Sustained Response up to Week 24 | 22.2 percentage of participants |
Secondary
Percentage of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs were AEs with onset during the double-blind treatment phase or that were a consequence of a preexisting condition that worsened since baseline.
Time frame: Up to 24 weeks
Population: The safety analysis set included all randomized participants who received at least 1 dose of study drug including the 2 participants who received the potentially defective IP.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Seltorexant | Percentage of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability | 65.4 percentage of participants |
| Quetiapine XR | Percentage of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability | 80.8 percentage of participants |
Secondary
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) and Events of Special Interest
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. AESIs were significant AEs that were judged to be of special interest because of clinical importance, known or suspected class effects, or based on nonclinical signals. Adverse events of special interest were cataplexy, sleep paralysis, complex, and sleep-related behaviors (parasomnias).
Time frame: Up to 24 weeks
Population: The safety analysis set included all randomized participants who received at least 1 dose of study drug including the 2 participants who received the potentially defective IP.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Seltorexant | Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) and Events of Special Interest | SAEs | 1.9 percentage of participants |
| Seltorexant | Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) and Events of Special Interest | AESIs | 13.5 percentage of participants |
| Quetiapine XR | Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) and Events of Special Interest | AESIs | 5.8 percentage of participants |
| Quetiapine XR | Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) and Events of Special Interest | SAEs | 3.8 percentage of participants |
Secondary
Percentage of Participants With Weight Gain of >=7% of Baseline Body Weight at Week 24
Percentage of participants with weight gain of \>=7% of baseline body weight at Week 24 were reported.
Time frame: At Week 24
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug including the 2 participants who received the potentially defective IP. Here, 'N' (numbers of participants analyzed) signifies number of participants evaluable for this outcome measure with at least one post-baseline value.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Seltorexant | Percentage of Participants With Weight Gain of >=7% of Baseline Body Weight at Week 24 | 4.3 percentage of participants |
| Quetiapine XR | Percentage of Participants With Weight Gain of >=7% of Baseline Body Weight at Week 24 | 8.5 percentage of participants |
Secondary
Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC)
Intensity of discontinuation symptoms was assessed (anxiety-nervousness, dysphoric mood/depression, Depersonalization-Derealization, , Diaphoresis, Diarrhea, Difficulty Concentrating, Remember, Dizziness-Lightheadedness, Fatigue-Lethargy-Lack of Energy, Headaches, Increased Acuity Sound Smell Touch, Irritability, Loss of Appetite, Muscle Aches or Stiffness, Nausea-Vomiting, Paresthesias, Poor Coordination, Restlessness-Agitation, Tremor-Tremulousness, Weakness), using the Physician Withdrawal Checklist (PWC-20) administered by a trained clinician/rater. Symptoms are rated on a scale of 0 (no symptom present), 1 (mild), 2 (moderate), and 3 (severe). Total scores range from 0 (no symptom) to 24 (severe symptom) calculated by adding the scores of following 8 items: Nausea-Vomiting, Diarrhea, Poor Coordination, Diaphoresis, Tremor-Tremulousness, Dizziness-Lightheadedness, Increased Acuity Sound Smell Touch, Paresthesias. Higher scores indicates more severe symptoms.
Time frame: Up to 26 weeks
Population: The safety analysis set included all randomized participants who received at least 1 dose of study drug including the 2 participants who received the potentially defective IP. Here, 'N' (numbers of participants analyzed) signifies numbers of participants evaluable for this outcome measure; 'n' (number analyzed) signifies those participants who were evaluable at specified timepoints. End Point (DB) is the last post baseline observation during the double blind phase.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Fatigue-Lethargy-Lack of Energy present (Endpoint[DB]) | 50.0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Diarrhea present (Endpoint [DB]) | 0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Depersonalization-Derealization present (Endpoint [DB]) | 0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Paresthesias present (Endpoint [DB]) | 0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Paresthesias present (Follow-up) | 3.3 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Headaches present (Endpoint [DB]) | 0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Poor Coordination present (Endpoint [DB]) | 25.0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Diaphoresis present (Endpoint [DB]) | 0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Poor Coordination present (Follow-up) | 10.0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Difficulty Concentrating, Remembering present (Follow-up) | 26.7 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Restlessness-Agitation present (Endpoint [DB]) | 25.0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Tremor-Tremulousness present (Endpoint [DB]) | 0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Increased Acuity for Sound, Smell, Touch, or Pain present (Endpoint [DB]) | 0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Tremor-Tremulousness present (Follow-up) | 3.3 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Weakness present (Endpoint [DB]) | 25.0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Weakness present (Follow-up) | 3.3 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Anxiety-Nervousness present (Follow-up) | 33.3 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Anxiety-Nervousness present (Endpoint [DB]) | 75.0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Diarrhea present (Follow-up) | 0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Dizziness-Lightheadedness present (Endpoint [DB]) | 0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Difficulty Concentrating, Remembering present (Endpoint [DB]) | 0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Dysphoric Mood-Depression present (Endpoint [DB]) | 50.0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Insomnia present (Endpoint [DB]) | 75.0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Fatigue-Lethargy-Lack of Energy present (Follow-up) | 33.3 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Headaches present (Follow-up) | 16.7 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Insomnia present (Follow-up) | 33.3 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Diaphoresis present (Follow-up) | 6.7 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Restlessness-Agitation present (Follow-up) | 26.7 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Irritability present (Endpoint [DB]) | 75.0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Dizziness-Lightheadedness present (Follow-up) | 23.3 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Irritability present (Follow-up) | 23.3 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Increased Acuity for Sound, Smell, Touch, or Pain present (Follow-up) | 6.7 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Depersonalization-Derealization present (Follow-up) | 6.7 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Loss of Appetite present (Endpoint [DB]) | 25.0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Muscle Aches or Stiffness present (Endpoint [DB]) | 50.0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Muscle Aches or Stiffness present (Follow-up) | 16.7 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Dysphoric Mood-Depression present (Follow-up) | 40.0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Nausea-Vomiting present (Endpoint [DB]) | 0 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Nausea-Vomiting present (Follow-up) | 3.3 percentage of participants |
| Seltorexant | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Loss of Appetite present (Follow-up) | 10.0 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Paresthesias present (Endpoint [DB]) | 0 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Anxiety-Nervousness present (Endpoint [DB]) | 33.3 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Depersonalization-Derealization present (Endpoint [DB]) | 0 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Depersonalization-Derealization present (Follow-up) | 0 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Diaphoresis present (Endpoint [DB]) | 0 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Diaphoresis present (Follow-up) | 10.7 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Diarrhea present (Endpoint [DB]) | 0 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Difficulty Concentrating, Remembering present (Endpoint [DB]) | 0 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Difficulty Concentrating, Remembering present (Follow-up) | 39.3 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Dizziness-Lightheadedness present (Endpoint [DB]) | 33.3 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Dizziness-Lightheadedness present (Follow-up) | 85.7 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Fatigue-Lethargy-Lack of Energy present (Endpoint[DB]) | 66.7 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Fatigue-Lethargy-Lack of Energy present (Follow-up) | 39.3 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Headaches present (Endpoint [DB]) | 33.3 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Headaches present (Follow-up) | 32.1 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Increased Acuity for Sound, Smell, Touch, or Pain present (Endpoint [DB]) | 0 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Increased Acuity for Sound, Smell, Touch, or Pain present (Follow-up) | 7.1 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Insomnia present (Follow-up) | 46.4 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Irritability present (Endpoint [DB]) | 66.7 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Irritability present (Follow-up) | 25.0 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Loss of Appetite present (Endpoint [DB]) | 66.7 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Muscle Aches or Stiffness present (Endpoint [DB]) | 33.3 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Nausea-Vomiting present (Endpoint [DB]) | 0 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Nausea-Vomiting present (Follow-up) | 17.9 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Paresthesias present (Follow-up) | 3.6 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Poor Coordination present (Endpoint [DB]) | 33.3 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Poor Coordination present (Follow-up) | 85.7 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Tremor-Tremulousness present (Endpoint [DB]) | 33.3 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Weakness present (Follow-up) | 14.3 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Diarrhea present (Follow-up) | 14.3 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Dysphoric Mood-Depression present (Endpoint [DB]) | 66.7 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Dysphoric Mood-Depression present (Follow-up) | 60.7 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Restlessness-Agitation present (Endpoint [DB]) | 33.3 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Restlessness-Agitation present (Follow-up) | 10.7 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Tremor-Tremulousness present (Follow-up) | 14.3 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Weakness present (Endpoint [DB]) | 33.3 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Insomnia present (Endpoint [DB]) | 66.7 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Loss of Appetite present (Follow-up) | 21.4 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Muscle Aches or Stiffness present (Follow-up) | 14.3 percentage of participants |
| Quetiapine XR | Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC) | Anxiety-Nervousness present (Follow-up) | 53.6 percentage of participants |